The release of the soluble form of tumor necrosis factor (TNF)-alpha from the plasma membrane occurs through the activation of the secretase tumor necrosis factor-alpha-converting enzyme (TACE). The current study was designed to examine whether the anti-Ro/SSA autoantibodies (Abs) are capable to regulate TACE expression in non-neoplastic human salivary gland epithelial cells (SGEC) cultures. We investigated the effect of anti-Ro/SSA Abs on the localization and abundance of cell-surface TACE and on TACE pro-domain-shedding and activation. In addition, the potential physiological consequences of TNF-alpha blockage by the biological agent Adalimumab on post-translational regulation of TACE are discussed. Anti-Ro/SSA Abs were purified from IgG fractions of patients with primary Sjö gren's syndrome, using Sepharose 4B-Ro/SSA affinity columns. Flow cytometry, reverse transcription-PCR, western blot and immunohistochemistry were used to study TACE expression on SGEC and TACE regulation by Abs. Our study demonstrated a dosedependent increase of TACE messenger RNA (mRNA) expression in anti-Ro/SSA Abs-treated SGEC, followed by internalization, pro-domain shedding and activation of TACE protein, suggesting that increased TACE activity is necessary for the release of TNF-alpha observed in anti-Ro/SSA Abs-stimulated SGEC. Adalimumab treatment brought TACE mRNA and surface TACE expression to levels than those observed in untreated SGEC. These data suggest that the effect of anti-Ro/SSA Abs on TACE expression and intracellular distribution is exerted by TNF-alpha production.
Introduction
Tumor necrosis factor-alpha-converting enzyme (TACE), the enzyme that processes precursor tumor necrosis factor (TNF)-alpha in order to release soluble TNF-alpha, is a member of the ADAM (a disintegrin and metalloproteinase) family and is known as ADAM17 (1, 2) . Like in the other members of the ADAM family, the structure of TACE is characterized by distinct domains that include a pro-domain, a metalloprotease and a disintegrin domain, followed by a cysteine-rich domain containing an epidermal growth factor (EGF)-like repeat, a transmembrane domain and a cytoplasmic tail (3) . The expression of TACE is ubiquitous and not limited to myeloid cells (1) (2) (3) (4) . Thus, it is not surprising that TNF-alpha is not the only substrate of TACE. The sheddase functions of TACE cover a broad range of numerous growth factors and growth factor receptors (3, 5) . As for other proteolytically active metalloprotease/disintegrins, two forms of TACE are found in cells; a full-length precursor and a mature form lacking the pro-domain (6) . Pro-domain removal occurs in a late Golgi compartment, consistent with the proposed role of a furin type proprotein convertase in this process (7) . Mature TACE was detected on the cell surface (6), but the mechanism by which TACE pro-domain shedding is regulated is poorly understood. Due to the firm evidence that TACE is the major TNF-alpha convertase, this enzyme has attracted considerable interest as a specific therapeutic target in diseases known to benefit from anti-TNF-alpha treatment including Crohn's disease and perhaps ulcerative colitis (8) . The cytokine TNF has an important role in inflammatory processes in rheumatoid arthritis (RA) and in other immune-mediated disorders. Consequently, TNF has emerged as an important target for the development of the therapeutic strategies for treating chronic autoimmune disorders. The TNF inhibitors that have been approved for clinical use to treat RA are infliximab, adalimumab and etanercept (9, 10) . Adalimumab (D2E7; Abbott Laboratories, Abbott Park, IL, USA), the first fully human (100% human peptide sequences) therapeutic mAb that blocks TNF-alpha, is currently being evaluated in clinical trials for the treatment of autoimmune disorders (11) . TACE is a target for anti-TNF therapy that is currently under investigation. Inhibitors of this enzyme with drug-like properties have been made and tested in the clinic. However, no studies aimed to elucidate the effects of anti-TNF-alpha blockers on TACE expression and activation have yet been published.
Results of our previous studies suggest that healthy human salivary gland epithelial cells (SGEC), established from biopsies of labial minor salivary glands of healthy donors, produce the cell death-inducing cytokine TNF-alpha when treated with the anti-Ro/SSA autoantibodies (Abs) (12) . Since TNF-alpha stimulates TACE expression in human cells (13) , an increased knowledge of the physiological mechanisms regulating TACE is of particular interest to help understand their roles in diseased conditions. The current study was, therefore, designed to examine whether anti-Ro/SSA Abs treatment is capable to regulate TACE expression in SGEC. We investigate the effect of anti-Ro/SSA Abs, purified from IgG fractions of patients with primary Sjö gren's syndrome (SS), on TACE pro-domain-shedding and activation and the potential physiological and therapeutic consequences of TNF-alpha blocking by the biological agent Adalimumab on post-translational regulation of TACE are discussed.
Methods

Labial minor salivary glands biopsies and SGEC culture
Labial minor salivary gland biopsies were obtained from 12 healthy individuals awaiting removal of salivary mucoceles from the lower lip. Informed consent from the patients and approval by the local ethics committee were obtained. The healthy subjects had no complaints of oral dryness, no autoimmune disease and normal salivary function. Labial minor glands were harvested from the lower lip under local anesthesia through normal mucosa. The explant outgrowth technique (14) was applied to establish non-neoplastic SGEC cultures from limited amounts of glandular tissue. The cells were isolated from the labial glands by microdissection and collagenase (Worthington Diagnostic Division, Millipore, Freehold, NJ, USA) digestion in physiological saline containing 1 mM Ca 2+ . Following dispersal, cells were resuspended in McCoy's 5a modified medium supplemented with 10% fetal bovine serum, 1% antibiotic solution, 2 mM L-Glutamine, 20 ng ml À1 EGF (Promega, Madison, WI, USA), 0.5 lg ml À1 insulin (Novo, Bagsvaerd, Denmark) and incubated at 37°C, 5% CO 2 in air. Contaminating fibroblasts were selectively removed by treatment of the cultures with 0.02% EDTA. The epithelial origin of cultured cells was routinely confirmed by staining with mAbs against epithelialspecific markers, including the various cytokeratins and epithelial membrane antigens and the absence of myoepithelial, fibroblastoid and lymphoid markers, using immunocytochemistry as previously described (15, 16) .
Purification of anti-Ro/SSA Abs
Anti-Ro/SSA Abs were purified from IgG fractions of patients with primary SS, all fulfilling the American-European Consensus Group Classification criteria for SS (17) , using human Ro/SSA antigen-Sepharose 4B affinity columns as described (18) . The Abs obtained were concentrated to 200 lg ml
À1
by ultrafiltration method and used at different concentrations in the experimental procedures. Abs preparations resulted free of endotoxin contamination, as assessed by a Limulus amebocyte assay (Sigma, St Louis, MO, USA).
Concentration of anti-Ro/SSA Abs used in TACE assays
Reverse transcription (RT)-PCR was used to determine the optimal concentration of anti-Ro/SSA Abs to employ in the experimental procedure. SGEC were cultured in complete McCoy's 5a modified medium at 37°C in the presence of various concentrations of anti-Ro/SSA (10, 25, 50 lg ml À1 ). After 24 h of incubation, cells were collected, washed twice and RT-PCR for TACE messenger RNA (mRNA) expression was performed according to the experimental procedure. The bands obtained were submitted to densitometric analysis using 1D Image Analyses Software (Kodak Digital Science, Rochester, NY, USA). The results are expressed as arbitrary units.
SGEC stimulation assays
SGEC were collected from culture media by centrifugation at 250 3 g and re-suspended at 1 3 10 6 cells per ml in McCoy's 5a modified medium supplemented with 10% fetal bovine serum, 1% antibiotic solution, 2 mM L-Glutamine, 20 ng ml À1 EGF and 0.5 lg ml À1 insulin. Cell suspension (10 5 cells per well) was added to each well of a six-well plate (Thomas Scientific, Swedesboro, NJ, USA) and allowed to incubate for 24 h at 37°C under 5% CO 2 . After incubation, cells were washed and treated as follows: (i) antiRo/SSA Abs (concentration of 50 lg ml À1 ) dissolved in McCoy's 5a for 24 h; (ii) IgG fractions extracted from sera of healthy donors (H IgG, 50 lg ml À1 ); (iii) Adalimumab (50 lg ml À1 ) for 24 h and (iv) treatment with 50 lg ml À1 of Adalimumab plus anti-Ro/SSA Abs (50 lg ml À1 ) for 24 h. Control was represented by untreated cells. Following incubation, cells were collected and analyzed for TACE expression.
Assay for TACE expression RNA isolation, complementary DNA synthesis and PCR. To determine the TACE mRNA expression, total RNA was extracted from variously treated SGEC using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's instructions. DNase-treated RNA (2 lg) was reverse transcribed to complementary DNA using the Superscript First Strand cDNA Synthesis kit (Invitrogen), according to the manufacturer's instructions. PCR was performed in a 50-ll reaction mixture composed of 2 lM of each sense and antisense primer, 13 PCR buffer, 2.4 mM MgCl 2 , 0.2 mM each dNTP, 10 ll of transcribed cDNA and 0.04 U/ll Taq DNA polymerase. After the initial denaturation at 94°C for 5 min, 35 cycles were used (denaturation at 94°C for 30 s, annealing at 58°C for 30 s and extension at 72°C for 1 min) followed by 10 min at 72°C. Equal amounts of PCR products were run on a 1.5% agarose gel containing ethidium bromide. The expected size of PCR products is 495 bp for GADPH, 380 bp for TACE. The primers were designed according to published sequences (reference source: www.ncbi.nlm.nih.gov). TACE were 5#-ACTGGAC-CACCAGAGAATGG-3# (sense) and 5#-GGCCAAACCACA-CAAGAACT-3# (antisense); GAPDH were 5#-TTCACCACCA-TGGAGAAGGC-3# (sense) and 5#-GGCATGGACTGTGGTC-ATGA-3# (antisense).
Characterization of RT-PCR products. All RT-PCR products visualized by agarose gel electrophoresis in Tris-acetate-EDTA buffer (40 mM Tris, pH 8.0, 40 mM acetic acid, 2 mM EDTA) followed by ethidium bromide staining were densitometrically analyzed, using gel image software (Bio-Profil Bio-1D; ltf Labortechnik GmbH, Wasserburg, Germany) after standardizing the amount of amplification product according to the expression of the housekeeping gene GADPH. Results were averaged from 12 sets of independent experiments and expressed as arbitrary units. The identities of the amplified fragments were confirmed by sequencing.
Real-time PCR assay. Total RNA from cultured cells was prepared and reverse transcription was conducted as described above. TaqMan expression assays, including fluorescent probes, forward and reverse primers for human TACE (Assays-On-Demand, Applied Biosystems, Foster City, CA, USA) and the internal control gene b-2 microglobulin (part no. 4326319E; b2M), were purchased from Applied Biosystems. All other reagents used in real-time PCR assays were purchased from the same manufacturer. Real-time quantitative PCR was performed in a 96-well microtiter plate with an ABI PRISM 7700 (Applied Biosystems). Each reaction contained 5 ll of cDNA template, 2.5 ll of 203 probe and primers mixture, 12.5 ll of TaqMan Universal PCR Master Mix, No AmpErase UNG (Applied Biosystems), in a total volume of 25 ll. Reactions were amplified for 40 cycles (65°C for 5 min and 95°C for 10 min, followed by 40 denaturation cycles at 95°C for 15 s and annealing and extension at 58°C for 1 min). The threshold was determined as 10 times the SD of the baseline fluorescence signal. The cycle number at the threshold was used as the threshold cycle (Ct). The different expression of TACE in untreated and treated samples was deducted from 2
ÀDDCt where DDCt = DCt variously treated cells À DCt untreated cells.
TACE protein expression. TACE protein levels were determined in treated and untreated control cells. We adopted different approaches to investigate TACE protein expression in SGEC, in absence or presence of anti-Ro/SSA Abs stimulation and/or Adalimumab addition, immunofluorescence, western blot and flow cytometry. In the immunofluorescence assay, variously treated SGEC were fixed for 10 min in 3.7% (v/v) PFA diluted in PBS plus 0.1% (v/v) Triton X-100. After treatment with 0.2% (w/v) BSA in PBS for 10 min, to minimize non-specific absorption of antibodies, the coverslips were incubated for 45 min at room temperature with the goat anti-human TACE pAb (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and for 30 min with the donkey anti-goat IgG-FITC (Santa Cruz Biotechnology). Finally, the slides were mounted and examined using a confocal laser scanning microscopy system (Leica, TCS-SP2, Germany) using a k = 488 nm Argon-Crypton laser for FITC. For western blot, SGEC were washed twice, detached, collected and centrifuged at 600 3 g for 10 min. The supernatant was removed and the pellet was incubated with lysis buffer [1% (v/v) Triton X-100, 20 mM Tris-HCl, 137 mM NaCl, 10% (v/v) glycerol, 2 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 20 lM leupeptin hemisulfate salt, 0.2 U/ml aprotinin] for 30 min on ice. After incubation, the obtained lysate was vortexed and then centrifuged at 12 800 3 g for 10 min; the protein concentration in the supernatant was spectrophotometrically determined by Bradford's protein assay, and the lysate was subjected to SDS-PAGE. Proteins (25 lg per lane) and prestained standards (BioRad Laboratories, Hercules, CA, USA) were loaded on 10% SDS-polyacrylamide precast gels. After electrophoresis, the resolved proteins were transferred from gel to nitrocellulose membranes. A blot buffer [20 Membranes were then incubated for 90 min with goat antihuman TACE pAb (Santa Cruz Biotechnology) and for 30 min with the donkey anti-goat IgG-HRP (Santa Cruz Biotechnology). Proteins recognized by the antibody were revealed using chemoluminescence luminal reagent (Santa Cruz Biotechnology) according to the protocol. As control for TACE protein expression, lysates from monocytes, obtained from healthy donors, treated or not with phorbol ester phorbol 12-myristate 13-acetate (PMA) for 12 h, were submitted to the same blot condition of SGEC. Monocytes are used widely as a positive control for TACE expression and function (1, 19) . The b-actin protein level was determined by western blot and used as a protein loading control. Surface TACE staining was performed in SGEC using flow cytometric analysis. SGEC were incubated with monoclonal anti-human TACE-PE Ab (R&D Systems, Minneapolis, MN, USA). Intracellular TACE staining was performed in permeabilized cells using the FACS permeabilizing 
ELISA analysis
The culture supernatants from cells cultured for 24 h in the absence or presence of anti-Ro/SSA Abs (50 lg ml À1 ) and/ or Adalimumab (50 lg ml À1 ) were tested for TACE contents using commercial ELISA kit (R&D, Abingdon, UK). Detection level for TACE was 10 pg ml
À1
.
Statistics
The data were analyzed for normality using the Wilks Shapiro Test. Differences in means for paired observations were analyzed by Student's t-test. In all instances, values of P < 0.05 were considered statistically significant.
Results
TACE is expressed in human SGEC
Human SGEC cultures were obtained from labial minor salivary gland biopsies of healthy individuals. Figure 1(A) , related to flow cytometric analysis, demonstrated the expression of TACE on the SGEC cell membrane. TACE expression was confirmed by immunofluorescence assay (Fig. 1B) that visualizes the intracellular distribution of TACE in untreated control SGEC and RT-PCR that shows clear TACE mRNA expression in untreated SGEC (Fig. 1C) .
Dose-dependent effects of anti-Ro/SSA Abs on the regulation of TACE mRNA expression
The studies performed indicated that the regulation of TACE mRNA expression in response to anti-Ro/SSA Abs is dose dependent, maximal effects of anti-Ro/SSA being obtained for doses at 50 lg ml À1 ( Fig. 2A-C) . The optimal concentration of 50 lg ml À1 for anti-Ro/SSA Abs was employed in all experimental procedures. When the SGEC were treated with H IgG (50 lg ml À1 ), no changes in TACE mRNA expression was observed in comparison with untreated SGEC (Fig. 3A and B) confirming the inability of H IgG to stimulate human SGEC, as demonstrated in our previous published works (18, 20) .
Effect of anti-Ro/SSA Abs stimulation
To investigate the potential effect of anti-Ro/SSA Abs treatment on TACE expression in SGEC, several methods were employed. The flow cytometric analysis investigated whether anti-Ro/SSA Abs treatment could modulate the cellular localization of TACE protein. SGEC were cultured in presence of anti-Ro/SSA Abs for 24 h and membrane TACE (surface TACE) and intracellular TACE expressions were assessed by using anti-human TACE mAb. Figure 4(A and B) , examples of flow cytometric images from one representative experiment, demonstrated that the percentage of untreated control SGEC that express membrane-bound TACE is 95 6 1.3%. Control SGEC predominantly express TACE on the cell surface [95 6 1.3%, mean fluorescence intensity (MFI) = 7008 6 150 for surface TACE versus 71 6 1.7%, MFI = 5980 6 127 for intracellular TACE, P < 0.01]. Surface TACE expression in untreated SGEC remained unchanged in the 24 h incubation period (MFI = 7008 6 1.5). After 24 h following anti-Ro/SSA Abs treatment, a decrease of surface TACE (67 6 1.32%, MFI = 4410 6 133) and an increase of intracellular TACE (98 6 1.78%, MFI = 15843 6 156) were observed (P < 0.01). Furthermore, 24 h following anti-Ro/ SSA Abs treatment, an increase of TACE protein synthesis was observed as demonstrated by the mean of the MFI (Fig. 4) .
To confirm the flow cytometric observations regarding TACE expression after 24 h of culture with anti-Ro/SSA Abs, we investigated TACE intracellular localization in permeabilized cells by confocal microscopy (Fig. 5A) demonstrating that anti-Ro/SSA Abs treatment determines an increase of TACE expression in structures diffusely present in the cytoplasm, in comparison with untreated control cells (Fig. 5A,a  and b) . For semiquantitative RT-PCR analysis, primary human SGEC cultures were treated with human anti-Ro/SSA Abs (50 lg ml
À1
) for a period of 24 h. As shown in Fig. 5 (B and C) as compared with untreated cells, expression of TACE gene was notably altered (>2-fold) in anti-Ro/SSA Abs-treated SGEC. These changes are in agreement with results obtained by real-time PCR (Fig. 5D ) that showed that the TACE mRNA copy number in untreated control cells was lower than in anti-Ro/SSA-treated cells. In order to investigate the post-translational regulation of TACE following antiRo/SSA Abs treatment, the presence of TACE protein was analyzed by western blotting (Fig. 5E) . A band corresponding to a full-length molecule containing the pro-domain was identified in untreated SGEC (110 kDa). Anti-Ro/SSA Abs treatment induces the appearance of TACE processed form devoid of pro-domain (85 kDa). The semiquantitative immunoblotting analysis revealed a significant increase of TACE protein synthesis (P < 0.05) following anti-Ro/SSA Abs treatment (Fig. 5F ) in comparison with untreated control SGEC. Interestingly, in monocytes obtained from healthy donors, the treatment with PMA not only induces the cleavage of TACE into mature form but also increases the amount of TACE protein. 
TACE is a target for Adalimumab
After Adalimumab treatment, membrane-bound TACE levels in anti-Ro/SSA-treated SGEC were restored (94 6 1.53%, MFI = 8540 6 144 for anti-Ro/SSA Abs plus Adalimumabtreated SGEC versus 67 6 1.32%, MFI = 4410 6 133 anti-Ro/SSA Abs-treated SGEC, P < 0.01). Adalimumab, moreover, did not determine a significant decrease of the percentage of cells that express intracellular TACE in antiRo/SSA Abs-treated SGEC (98 6 1.78% for anti-Ro/SSA Abs-treated SGEC versus 95 6 1.8% for anti-Ro/SSA plus Adalimumab Abs-treated SGEC), but a remarkable significant (P < 0.01) decrease of MFIs was observed (MFI = 15843 6 156 for anti-Ro/SSA Abs-treated SGEC versus MFI = 7407 6 163 for anti-Ro/SSA plus Adalimumab Abs-treated SGEC). Notably, treatment of SGEC with Adalimumab alone did not affect the surface and intracellular TACE levels in comparison with untreated control cells (93 6 1.27%, MFI = 7381 6 139 for surface TACE in Adalimumab-treated SGEC versus 95 6 1.3%, MFI = 7008 6 150 for surface TACE in untreated cells; 75 6 1.89%, MFI = 5691 6 127 for intracellular TACE in Adalimumab-treated SGEC versus 71 6 1.7%, MFI = 5980 6 127 in untreated cells) (Fig. 4) . Data related to mean of MFI were reported in Fig. 4C .
In anti-Ro/SSA Abs-treated cells, Adalimumab produced a decreased intracellular TACE expression reporting the immunofluorescence signal to that observed in untreated SGEC (Fig. 5A,c) . RT-PCR and real-time PCR analyses demonstrated that Adalimumab restored the TACE mRNA levels observed in untreated control cells (Fig. 5C  and D) . In addition, western blot revealed that when treated with Adalimumab plus anti-Ro/SSA Abs, SGEC predominantly express the inactive proform of TACE (Fig. 5E ).
Anti-Ro/SSA Abs induce TACE internalization in SGEC
Whether modulation of TACE mRNA and protein expression, regulated by anti-Ro/SSA Abs treatment, was accompanied by the concomitant release of soluble TACE was assessed by ELISA in the conditioned media of anti-Ro/SSA Abs-treated SGEC. However, no detectable levels of soluble TACE were found (Fig. 6 ).
Discussion
The experiments described herein were undertaken in an attempt to demonstrate TACE expression on human SGEC and to elucidate the mechanisms by which the anti-Ro/SSA Abs activate TACE pro-domain shedding. Anti-Ro/SSA Abs stimulation of human SGEC appeared to have an effect on TACE localization and expression, suggesting that increased TACE activity is necessary for the release of TNF-alpha observed in anti-Ro/SSA Abs-stimulated cells.
The presence of the TACE protein in human SGEC has not been previously described but this is not surprising in light of the ubiquitous expression of this sheddase in a variety of non-immune human cells, including endothelial cells, small muscle cells, chondrocytes and human colonic epithelial cells (1-4) . We used flow cytometric analysis and immunohistochemistry to localize TACE protein in human SGEC. A strong immunoreactivity for TACE protein was observed, as expected, in these cells. These data were confirmed by western blotting of cellular protein lysate showing that untreated SGEC express the inactive form of TACE protein.
The fundamental nature of the biological processes controlled by TACE proteinase means that dysregulation of this enzyme will inevitably contribute to pathogenic mechanisms of human diseases. TACE have been implicated in cancer (21) , neurological (22) and cardiovascular diseases (23) , asthma (24) and infection (25) . In autoimmune diseases, upregulation of TACE was recently demonstrated in inflammatory synovial tissue from patients with RA, in PBMC of patients with multiple sclerosis (26) (27) (28) and an altered TACE activity in Crohn's disease mucosa has been suggested (8) . However, a correlation between Abs production characterizing autoimmune diseases and TACE expression has not previously been investigated. To our knowledge, our report provides the first observation of a relation between TACE and pathogenic Abs.
Growing evidence indicates that expression of the TACE gene can be regulated. Increased levels of TACE mRNA were observed in HL-60 cells stimulated with LPS (29) , in murine retinal endothelial cells exposed to vascular endothelial growth factor (30) and in osteoarthritis-and RA-affected cartilage (27) . Our study demonstrated a dose-dependent increase of TACE mRNA expression in anti-Ro/SSA Abstreated SGEC (Fig. 2 and Fig. 5C and D) .
Since Abs were shown to induce the increase of TACE mRNA synthesis, we could expect an increase in TACE protein concentration after treatment with anti-Ro/SSA Abs. This hypothesis was confirmed by the increase of the mean of the MFI observed through flow cytometric analysis (Fig. 4) .
We next tested the possibility that anti-Ro/SSA Abs treatment of SGEC could determine TACE activation through pro-domain shedding. Western blotting revealed the mature form of enzyme in anti-Ro/SSA Abs-treated SGEC (Fig. 5E) . The mechanism by which TACE shedding was activated, following anti-Ro/SSA Abs treatment of SGEC, was investigated by analyzing whether the treatment could modulate the cellular localization of TACE protein. Treatment of the cells for 24 h with 50 lg ml À1 anti-Ro/SSA Abs affected the cellular amount and distribution of TACE. In fact, as shown in Fig. 5(A) , anti-Ro/SSA Abs treatment determines an increase of TACE expression, in structures diffusely present in the cytoplasm, in comparison with untreated control cells (Fig. 5A,a and b) . The different localization of TACE in response to Abs suggests a TACE pro-domain removal following internalization stimulated by anti-Ro/SSA Abs. If TACE pro-domain removal occurs in our experiments, we would expect to detect a cell-associated remaining transmembrane fragment after proteolysis. We compared the levels of TACE in lysates of unstimulated and anti-Ro/SSA Abs-stimulated cells by western blot analysis performed with anti-human TACE antibody raised against the catalytic domain of TACE. A band of 110 kDa corresponding to the inactive TACE protein is clearly visible only in the lysates from untreated control SGEC. Instead, a band of 85 kDa, probably corresponding to the mature form of the protein, is only detectable in anti-Ro/ SSA Abs-stimulated cells (Fig. 5E) . To detect the presence of any soluble fragment of TACE, an ELISA test was performed on the conditioned media of anti-Ro/SSA Abs-treated SGEC. However, no soluble forms of TACE were found, leading us to hypothesize that TACE might be internalized in response to Abs.
Based on these observations, we speculate that the induction of TACE pro-domain shedding by anti-Ro/SSA Abs treatment might be due to a stimulated movement of inactive TACE from the membrane to the intracellular compartment, where pro-domain shedding occurs, followed by trafficking of active TACE from intracellular stores to the plasma membrane. Several authors have suggested TACE internalization in response to cellular stimulation (19, 31, 32) . Our current findings support this assertion. In fact, soluble TACE was not detected in the medium of anti-Ro/SSA Abs-treated SGEC, and a flow cytometric analysis demonstrated an antiRo/SSA Abs-mediated decrease of surface TACE in SGEC correlated with an increase in intracellular TACE, implying that cell-surface TACE was internalized in response to Abs (Fig. 4) . These observations suggest that cell-surface TACE is redistributed to an intracellular compartment in response to Abs.
To further address the question whether there is a correlation between pro-domain shedding, activation, TACE internalization and release of TNF-alpha protein observed in SGEC upon anti-Ro/SSA Abs treatment (12), we used Adalimumab to block TNF-alpha and evaluated the effects of this biological agent on TACE mRNA and protein expression. In the present work, we found that in anti-Ro/SSA Abs-treated SGEC, Adalimumab has an effect both on TACE gene and protein expression. Adalimumab treatment brought TACE mRNA and surface TACE expression to marginally higher levels than those observed in untreated SGEC, as shown by RT-PCR, real-time PCR and flow cytometry. These data were confirmed by immunohistochemistry and western blot, demonstrating that anti-Ro/SSA Abs plus Adalimumab-treated SGEC express the inactive proform of TACE predominantly on the plasma membrane (Fig. 5) .
Taken together, the results obtained suggested the hypothesis that the effect of anti-Ro Abs on TACE expression and intracellular distribution in SGEC is exerted by TNFalpha production. Thus, it is intriguing to consider that TACE regulation may participate in the pathogenic role of Abs.
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